1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health and behavioural conditions
  5. Dementia

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Review decision
  • Review decision - April 2015
  • Appendix A: review decision paper 28 April 2015   PDF 120.27 KB
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.